Spironolactone Dosing in Pediatric Heart Failure
Start spironolactone at 1 mg/kg/day in children with heart failure, with a target maximum dose of 2 mg/kg/day, typically initiated after ACE inhibitor and β-blocker therapy has failed to improve ventricular function. 1
Dosing Algorithm
Initial Dosing
- Starting dose: 1 mg/kg/day (given once daily or divided doses)
- Target maximum: 2 mg/kg/day (tolerated by most patients) 1
- Initiate only after inadequate response to ACE inhibitor and β-blocker therapy 1
Timing of Initiation
Spironolactone should be added when:
- ACE inhibitor and β-blocker therapy has not resulted in improved ventricular function
- No reversal of ventricular remodeling has occurred despite optimal medical therapy 1
Critical Safety Monitoring
Hyperkalemia Risk
Check potassium and renal function:
- Before starting spironolactone
- Within 7-14 days after initiation
- Periodically thereafter 1
The combination of spironolactone with ACE inhibitors significantly increases hyperkalemia risk, especially with compromised renal function 1, 2, 3. A case report documented severe hyperkalemia (8.9 mEq/L) in a 2-month-old on concomitant enalapril and spironolactone, which resolved within 72 hours of spironolactone discontinuation 3.
Potassium Supplementation
Carefully re-evaluate any potassium supplementation when initiating spironolactone 1. Recent evidence shows spironolactone substantially reduces potassium replacement needs by 48-96 hours of therapy 4.
Important Caveats
Non-Reversible Adverse Effect
Male gynecomastia is non-reversible and must be closely monitored 1. This is a dose-dependent complication that can occur from 1-2 months to over a year after initiation 2.
Pharmacokinetic Considerations
Recent pharmacokinetic data in infants up to 2 years shows highly variable drug disposition, with body weight explaining 22% of inter-individual variability in spironolactone clearance 5. This supports weight-based dosing but highlights the need for individualized monitoring in very young patients.
Limited Pediatric Evidence
The guideline explicitly acknowledges that data regarding spironolactone in pediatric heart failure are very limited 1. The dosing recommendations are largely empirical, extrapolated from adult data where aldosterone antagonism reduces mortality in systolic heart failure.
Monitoring Parameters Beyond Potassium
Monitor for:
- Hyponatremia, hypomagnesemia, hypocalcemia
- Hypotension and worsening renal function
- Hyperglycemia and hyperuricemia 2